Abl Diagnostics (ABLD) | Financial Analysis & Statements
Abl Diagnostics Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2022Income Metrics
Revenue
2.4B
Gross Profit
1.5B
61.04%
Operating Income
1.4B
58.12%
Net Income
1.0B
41.67%
EPS (Diluted)
€2.80
Balance Sheet Metrics
Cash Flow Metrics
Operating Cash Flow
2.1B
Free Cash Flow
2.2B
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2022
Annual Income Flow
2024
Abl Diagnostics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 5.3M | 5.6M | 8.7M | 0 | 0 |
| Cost of Goods Sold | 494.2K | 734.5K | 426.7K | 101.6K | 87.2K |
| Gross Profit | 4.8M | 4.9M | 8.3M | -101.6K | -87.2K |
| Gross Margin % | 90.7% | 86.9% | 95.1% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | - | - | - |
| Other Operating Expenses | 3.0M | 3.5M | 6.4M | 102.6K | 91.2K |
| Total Operating Expenses | 3.0M | 3.5M | 6.4M | 102.6K | 91.2K |
| Operating Income | -484.2K | -657.1K | 59.3K | -102.6K | -91.2K |
| Operating Margin % | -9.1% | -11.7% | 0.7% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 63.4K | 43.5K | 31.0K | 11 | 1.9K |
| Interest Expense | 72.8K | 54.1K | 12.8K | - | - |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -496.3K | -670.9K | 77.5K | -102.6K | -89.3K |
| Income Tax | -722.1K | -678.2K | -615.2K | 38.1K | - |
| Effective Tax Rate % | 0.0% | 0.0% | -793.8% | 0.0% | 0.0% |
| Net Income | 285.2K | 54.4K | 1.1M | 257.9K | -89.3K |
| Net Margin % | 5.3% | 1.0% | 12.6% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | 313.1K | 45.4K | 651.1K | -102.6K | -91.2K |
| EPS (Basic) | €0.02 | €0.00 | €0.07 | €0.13 | €-0.04 |
| EPS (Diluted) | €0.02 | €0.00 | €0.07 | €0.13 | €-0.04 |
| Basic Shares Outstanding | - | 16113904 | 16113904 | 2006480 | 2006480 |
| Diluted Shares Outstanding | - | 16113904 | 16113904 | 2006480 | 2006480 |
Income Statement Trend
Abl Diagnostics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 468.8K | 2.2M | 1.0M | 2.7M | 2.4M |
| Short-term Investments | 60.5K | 94 | 94 | 94 | - |
| Accounts Receivable | 3.2M | 4.0M | 3.9M | - | - |
| Inventory | 699.4K | 707.4K | 665.3K | - | - |
| Other Current Assets | -1 | 3.7M | -1 | - | - |
| Total Current Assets | 8.4M | 11.6M | 12.0M | 2.7M | 2.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 846.7K | 712.2K | 826.9K | - | 0 |
| Goodwill | 2.7M | 2.5M | 2.3M | 0 | 0 |
| Intangible Assets | 2.7M | 2.5M | 2.3M | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -1 | 1 | -1 | - | -1.5K |
| Total Non-Current Assets | 3.4M | 3.3M | 3.4M | 0 | 1.5K |
| Total Assets | 11.8M | 14.9M | 15.4M | 2.7M | 2.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.4M | 3.2M | 4.4M | 55.9K | 16.7K |
| Short-term Debt | 629 | 1.3K | - | 312 | 1.4K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 837 | 626.2K | 366.8K | - | - |
| Total Current Liabilities | 1.8M | 4.7M | 6.0M | 94.3K | 18.1K |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.6M | 3.5M | 2.7M | - | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | 366.8K | - | - |
| Total Non-Current Liabilities | 2.6M | 3.5M | 2.7M | 0 | 0 |
| Total Liabilities | 4.3M | 8.1M | 8.7M | 94.3K | 18.1K |
| Equity | |||||
| Common Stock | 1.6M | 1.6M | 1.6M | 2.0M | 2.0M |
| Retained Earnings | 2.2M | 1.5M | 1.5M | 168.6K | -89.3K |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 7.5M | 6.8M | 6.8M | 2.6M | 2.4M |
| Key Metrics | |||||
| Total Debt | 2.6M | 3.5M | 2.7M | 312 | 1.4K |
| Working Capital | 6.7M | 6.9M | 6.0M | 2.6M | 2.4M |
Balance Sheet Composition
Abl Diagnostics Cash Flow Statement From 2017 to 2021
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 257.9K | -89.3K | -62.9K | 1.6M | -25.1K |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 0 | 0 | -115.5K | 273.4K | 199.9K |
| Operating Cash Flow | 257.9K | -89.3K | -178.4K | 1.9M | 174.8K |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | 400.0K | - | - | 6.0M | 400.9K |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 400.0K | - | - | 6.0M | 400.9K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - |
| Free Cash Flow | -56.7K | 29.5K | -278.4K | -563.3K | 370.2K |
| Net Change in Cash | 657.9K | -89.3K | -178.4K | 7.9M | 575.7K |
Cash Flow Trend
Abl Diagnostics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
92.00
Forward P/E
46.00
Price to Book
5.94
Price to Sales
7.12
Profitability Ratios
Profit Margin
7.44%
Operating Margin
-2.01%
Return on Equity
6.73%
Return on Assets
-1.38%
Financial Health
Current Ratio
4.00
Debt to Equity
38.66
Beta
-0.55
Per Share Data
EPS (TTM)
€0.03
Book Value per Share
€0.47
Revenue per Share
€0.41
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ABLD | 44.4M | 92.00 | 5.94 | 6.73% | 7.44% | 38.66 |
| Cegedim S.A | 188.1M | 92.86 | 0.54 | -4.95% | -2.25% | 115.34 |
| Smaio S.A | 47.0M | 16.30 | 5.78 | -24.00% | -22.35% | 41.76 |
| Intrasense S.A | 11.8M | - | - | -314.39% | -244.82% | -0.21 |
| Media Lab S.p.A | 8.1M | 18.89 | 5.88 | 35.13% | 23.18% | - |
Financial data is updated regularly. All figures are in the company's reporting currency.